Assessment of the utility of Hoesch test assay as initial screening test for acute hepatic porphyria in Japan - Assessment of the utility of Hoesch test assay as initial screening test for acute hepatic porphyria in Japan

开始日期2024-05-01

申办/合作机构

Saga University

JPRN-UMIN000052985 / SuspendedN/AIIT

Association of hypnotics or antipsychotics with in-hospital falls or fall injuries: a multicenter retrospective study - Association of hypnotics with in-hospital falls: a multicenter retrospective study

开始日期2023-12-15

申办/合作机构

Saga University

100 项与 Saga University 相关的临床结果

登录后查看更多信息

0 项与 Saga University 相关的专利（医药）

登录后查看更多信息

11,457

项与 Saga University 相关的文献（医药）

2025-01-01·SEPARATION AND PURIFICATION TECHNOLOGY

Mechanistic deduction of gallium(III) extraction using halogenated secondary amides: Spectroscopic interpretation

作者: Song, Xi-Ming ; Ohto, Keisuke ; Pang, Gehui ; Kawakita, Hidetaka ; Morisada, Shintaro

Secondary amides act as bifunctional compounds to extract metal anionic species due to the presence of N-H hydrogen and protonated carbonyl oxygen atoms.To exclude the latter function with stronger interaction and less extraction selectivity for metal anionic species, two secondary amide compounds with halogen atoms, namely N-(2-ethylhexyl)-2,2,2-trichloroacetamide as TCAA and N-(2-ethylhexyl)-2,2,2-tribromoacetamide as TBAA, have been synthesized to investigate the efficiency and mechanism of Ga(III) extraction for comparison with N-(2-ethylhexyl)-2,2,2-trifluoroacetamide (TFAA).The 1H NMR spectroscopy results indicated the absence of proton extraction from the carboxylic oxygen atoms of both halogen-containing amides at sufficiently high concentrations of HCl.The three amides exhibited preferential extraction of Ga(III) compared to other metals in highly acidic media.A slope anal. was conducted to assess the stoichiometry for the extraction of Ga(III).The FT-IR and ¹H NMR spectroscopies were employed to elucidate the extraction mechanism of GaCl^-₄ using TCAA and TBAA.Therefore, the hydrogen atoms of the N-H group of both amides, with extremely weak δ+ nature, exhibited a distinct extractive preference for anionic GaCl^-₄.Following the forward extraction, Ga(III) was effectively separated from the organic phase through stripping with distilled water.The extraction efficiencies of GaCl^-₄ among the three amides are not followed by the strength of electron-withdrawing nature of halogen atoms, but the strength of intra- or intermol. interactions of the amides.This argument was substantiated by calculations using d. functional theory (DFT).

2024-12-01·JOURNAL OF HYPERTENSION

Mechanisms of thiazide-induced hypertension treatment: insights from gene expression and histological analysis in malignant stroke-prone spontaneously hypertensive rats

Article

作者: Higashino, Hideaki ; Higashino, Toshihide ; Matsumoto, Akiko ; Ashenagar, Mohammad Said

Objective::

Diuretics, including thiazides and thiazide-like drugs, are commonly recommended for treating hypertension, though their precise mechanism of action is not fully understood. This study aimed to investigate the pharmacological effects of trichloromethiazide (TCM) in malignant stroke-prone spontaneously hypertensive rats (M-SHRSP).

Methods::

M-SHRSPs were treated with varying doses of TCM. Prognosis, histological changes, and mRNA expression related to hypertension and stroke were assessed.

Results::

The high-dose TCM group (3%) exhibited significantly lower SBP compared with the untreated group, whereas the low-dose group (0.3%) did not show a significant reduction in SBP. The survival rate was 54% in the low-dose group, whereas all rats in the high-dose group survived without experiencing a stroke by 16 weeks of age. Organ weights in both TCM-treated groups were lower than those in the control group, without severe histological abnormalities, including stroke and sclerosis. Plasma levels of thiobarbituric acid-reactive substances (TBARS) were significantly reduced in both TCM-treated groups. Additionally, 20 genes related to tissue protection, repair, proliferation, maintenance, and function were significantly expressed.

Conclusion::

TCM administration in M-SHRSPs significantly modulated the expression of 20 genes associated with tissue protection and maintenance, and reduced plasma TBARS levels. These findings suggest that TCM, a thiazide diuretic, may protect against tissue impairment in hypertension by modulating gene expression and exhibiting antioxidant activity.

2024-12-01·PREVENTIVE MEDICINE

Association between physical activity and the N-terminal pro-brain natriuretic peptide in a middle-aged Japanese population: The interaction with alcohol consumption, 2005–2006

Article

作者: Iwasaka, Chiharu ; Tanaka, Keitaro ; Nanri, Hinako ; Nakamura, Kazuyo ; Shimanoe, Chisato ; Sakamoto, Tatsuhiko ; Nishida, Yuichiro ; Hara, Megumi ; Furukawa, Takuma ; Taguchi, Naoto ; Shinchi, Koichi ; Higaki, Yasuki ; Horita, Mikako ; Imaizumi, Takeshi

OBJECTIVE:

Higher N-terminal pro-brain natriuretic peptide (NT-proBNP) levels are a strong risk factor for cardiovascular disease. The current study aimed to clarify the cross-sectional association of physical activity (PA) with NT-proBNP and to identify the interaction of PA with alcohol consumption or cigarette smoking in middle-aged individuals.

METHODS:

The study included 4613 individuals (1824 men and 2789 women) (November 2005-November 2006). Total PA, steps, light-intensity PA (LPA), and moderate-to-vigorous-intensity PA (MVPA) were assessed using accelerometer. Serum NT-proBNP levels were measured. Cross-sectional associations of total PA and steps with NT-proBNP were analyzed using multiple regression with adjustment for potential confounders. The isotemporal substitution model was used to assess activity intensity-specific association. The interaction between PA and alcohol consumption or smoking was also examined.

RESULTS:

Total PA was independently and inversely associated with NT-proBNP in the entire sample (P = 0.04). The inverse association of substituting LPA with MVPA for NT-proBNP was clearer in men than in women (P_interaction = 0.04). Inverse associations of total PA or steps with NT-proBNP were clearer in heavy drinkers than in moderate drinkers and non-drinkers in the entire sample (P_interaction < 0.05). In men, the inverse association of substituting LPA with MVPA for NT-proBNP was also clearer in heavy drinkers (P_interaction = 0.02). No interactions of PA with smoking were detected.

CONCLUSIONS:

Higher total PA was associated with better NT-proBNP in middle-aged individuals. Additionally, the effect of substituting LPA with MVPA on NT-proBNP was greater in men than in women. Furthermore, the association between PA and NT-proBNP may be modified by alcohol consumption.

项与 Saga University 相关的新闻（医药）

2024-04-17

·NS Medical Devices

BostonGene, Saga University partner to discover biomarkers for NSCLC

The collaboration will conduct a study that will evaluate the tumour microenvironment (TME) using the BostonGene Tumour Portrait test, which uses tissue samples collected before EGFR-TKI treatment and before ICI administration BostonGene, Saga University collaborate on biomarkers. (Credit: Julia Koblitz on Unsplash) BostonGene has teamed up with Japan’s Saga University to discover biomarkers for immunotherapy (IO) treatment response and treatment-related toxicity in advanced non-small cell lung cancer (NSCLC) patients. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferred treatment options for advanced NSCLC patients with EGFR mutations. According to BostonGene, the acquired resistance often leads to recurrence within a couple of years, presenting a challenge for post-treatment optimisation. Immune checkpoint inhibitors (ICIs) are standard therapy for NSCLC, but they lack efficacy in EGFR mutation-positive cases. However, combination therapy with ICIs and anti-angiogenic agents has shown promise in EGFR-positive lung cancer. The collaboration will conduct a study that will evaluate the tumour microenvironment (TME) using the BostonGene Tumour Portrait test. The test will use tissue samples collected before EGFR-TKI treatment and before ICI administration in patients with EGFR-positive lung adenocarcinoma. The study will examine the relationship between TME characteristics and the effectiveness of ICIs in these patients and investigate TME changes resulting from EGFR-TKI therapy. Saga University professor Naoko Aragane said: “By partnering with BostonGene, we aim to uncover novel biomarkers to revolutionize how we approach immunotherapy treatment in EGFR-positive lung cancer, ultimately improving patient outcomes.” The researchers will review cases where small-cell transformation due to EGFR-TKI resistance, to elucidate the molecular mechanisms underlying the transformation. They will enhance the understanding of TME dynamics and its implications for treatment response, informing improved therapeutic strategies for EGFR-positive lung adenocarcinoma. In 2023, BostonGene, NEC Corporation and Japan Industrial Partners established a joint venture, dubbed BostonGene Japan. The JV leverages BostonGene’s advanced molecular technology and NEC’s biocomputational algorithms. It aims to deliver personalised tests to cancer patients in Japan and collaborate with academic and industry partners to advance the development of targeted therapies. BostonGene chief medical officer Nathan Fowler said: “Our collaboration with Saga University underscores our dedication to advancing the standard of care in Japan by bringing novel technologies to the region. “The study marks an opportunity to delve deep into the complexities of the tumour microenvironment in EGFR-positive lung cancer patients, equipping oncologists with more targeted and effective immunotherapy strategies for their patients.”

免疫疗法临床研究

2024-04-16

·BioSpace

BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients

Study designed to explore novel markers for identifying responders with immune checkpoint inhibitors in patients resistant to targeted therapies WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and Saga University located in Saga, Japan and known for its commitment to educating and training researchers and professionals in the medical and healthcare fields, announced today the launch of a collaboration aimed at discovering biomarkers for immunotherapy (IO) treatment response and treatment-related toxicity in advanced non-small cell lung cancer (NSCLC) patients. This press release features multimedia. View the full release here: EGFR-TKI treatment effectively targets EGFR mutation-positive NSCLC. Still, acquired resistance often leads to recurrence within 1 to 2 years, presenting a challenge for post-treatment optimization. Immune checkpoint inhibitors (ICIs) are standard therapy for NSCLC, but the efficacy in EGFR mutation-positive cases is limited. However, combination therapy with ICIs and anti-angiogenic agents has shown promise in EGFR-positive lung cancer. This study will evaluate the tumor microenvironment (TME) utilizing the BostonGene Tumor Portrait™ test in tissue samples collected before EGFR-TKI treatment and before ICI administration in patients with EGFR-positive lung adenocarcinoma. The study aims to examine the relationship between TME characteristics and the effectiveness of ICIs in these patients and investigate TME changes resulting from EGFR-TKI therapy. Furthermore, researchers will review cases where small-cell transformation occurred as a mechanism of EGFR-TKI resistance, aiming to elucidate the molecular mechanisms underlying this transformation within the TME context. By addressing these objectives, we enhance our understanding of TME dynamics and its implications for treatment response, ultimately informing improved therapeutic strategies for EGFR-positive lung adenocarcinoma. “We are dedicated to advancing medical research directly impacting patient care. By partnering with BostonGene, we aim to uncover novel biomarkers to revolutionize how we approach immunotherapy treatment in EGFR-positive lung cancer, ultimately improving patient outcomes,” said Dr. Naoko Aragane, Professor of Saga University. “Our collaboration with Saga University underscores our dedication to advancing the standard of care in Japan by bringing novel technologies to the region. The study marks an opportunity to delve deep into the complexities of the tumor microenvironment in EGFR-positive lung cancer patients, equipping oncologists with more targeted and effective immunotherapy strategies for their patients,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. BostonGene, NEC Corporation and Japan Industrial Partners established BostonGene Japan Inc., a joint venture leveraging BostonGene's advanced molecular technology and NEC's biocomputational algorithms in 2023. The company aims to deliver its industry-leading personalized tests to cancer patients in Japan and collaborate with academic and industry partners to accelerate the development of targeted therapies. About BostonGene Corporation BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth pro the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at .

免疫疗法临床研究

100 项与 Saga University 相关的药物交易

登录后查看更多信息

100 项与 Saga University 相关的转化医学

登录后查看更多信息